We expect the growth to continue as we gain ground in the domestic custom cranial implant market.  We are currently working on reaching out to the international market this year and believe this will have a direct positive benefit to our bottom line.   Kelyniam is extremely excited to open up new markets and hopes to capitalize on those with new product lines in the near future, stated President and CEO Tennyson Anthony.

Mark Chenoweth, Vice President of Sales commented “We continue to make significant progress in building our presence in hospitals, teaching institutions, and trauma centers across the U.S. The weekly feedback we receive from surgeons who are using our implants has been excellent. They are realizing the benefits of our fast turnaround capabilities, and are thrilled with the time and effort we save them in the O.R. due to our precision fitting implants.   With our unique product offering, we look forward to another exciting 2nd Quarter, providing both the surgeons and patients the best custom skull implant option available in the market today.”

The CPA firm, Sadler, Gibb & Associates, has compiled the balance sheet and income statement for Kelyniam for the period end March 31, 2012.  No audit has been performed on the statements presented.

A proxy has been distributed to shareholders of record March 27^th regarding the annual meeting scheduled for May 11^th at the company’s headquarters.  Shareholders are reminded to vote and return proxies no later than 2pm EST on May 9, 2012.

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

For Question regarding this Press Release, please contact:

Kelyniam Global Inc.
Michael Hamblett, 800-280-8192  x3

Director of Investor Relations

While Kelyniam only received the 510k approval for Custom Skull Implants (CSI) in April of 2011, the company was thrilled to be able to receive and fulfill several orders during the 3rd quarter, even before our commercial launch in September.  Revenues for the 3rd quarter of 2011 were $63,821.  This clearly demonstrates demand for our product.

4th quarter revenues were $46,800.  Fewer surgeries were scheduled around the holidays in December and due to the real-time and custom nature of our products some orders were pushed into the first quarter of 2012.  This resulted in 4th quarter revenues slightly lower than Q3 revenues.   “2011 closes a year of major milestones for Kelyniam.  We look forward to building on the momentum in 2012,” said President and CEO Tennyson Anthony.

The unaudited revenues for the 3rd and 4th quarter of 2011 are as follows:

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG.PK - News), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

For Question regarding this Press Release, please contact:

Kelyniam Global Inc.
Michael Hamblett, 800-280-8192 x3
Director of Investor Relations

Canton, CT – December 13, 2011 Kelyniam Global, Inc (Pinksheets: KLYG), an emerging medical device manufacturing company, announced today it has successfully demonstrated the ability to provide a PEEK-OPTIMA® Custom Skull Implant in as little as 24 hours.

On Saturday, November 26^th, at 5:30pm, Kelyniam received the patient’s uploaded CT-Data. By 3:30 pm Sunday, the following day, a completed, precision designed, PEEK-OPTIMA® Custom Skull Implant was delivered to the hospital, meeting the needed requirements and a successful procedure soon followed. Until now, 24-hour turn-around service has not been an option offered to surgeons by any other company in the custom cranial implant market.

Kelyniam’s President and CEO, Tennyson S. Anthony stated: “We were challenged with an “emergency case” and we proved that Kelyniam could provide the surgeon with the required implant within a 24 hour time frame. We want everyone to understand that they can “re-think” the way they have ordered custom cranial implants in the past, no longer needing to schedule surgeries with a 4-6 week lead time due to slow turnaround times.”  Mr. Anthony added: “Surgeons across the U.S. are reporting unmatched precision and results using Kelyniam’s Custom Skull Implants. Whether it’s a need for precision fit, proven PEEK material, or fast turnaround, Kelyniam is prepared to deliver to the world. We are proud of our accomplishments and promise to never compromise with product or patient care. We believe our fast turnaround time provides surgeons additional treatment options, and improves the patient’s quality of life by getting them on the path to recovery in less time.”

Kelyniam Custom Skull Implants (CSI) are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma, disease or congenital birth defects. Streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver precision fit, patient specific implants to surgeons in as little as 24 hours from the receipt of an order if needed.

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

“Kelyniam Global is a relatively young company with incredible potential.  It is thrilling to be a part of an organization that is on the cutting edge and striving to lead the industry.  I look forward to working hard to make Kelyniam Global the leader in the custom implant market.”

As well, Kelyniam announced the appointment of Christopher Breault to the position of Vice President of Operations.  Mr. Breault has been involved with the custom implant industry for over six years and brings innovation and expertise that has resulted in significantly reducing the turnaround time for the production of our custom implants.  This time reduction together with drastic improvements on efficiency all add to our competitive edge and ultimately our bottom line.

Canton, CT — October 17, 2011 Kelyniam Global, Inc. (Pinksheets: KLYG), an emerging medical device manufacturing company, announced today it has completed its filing process with the Central Contractor Registration (CCR) and has received approval to sell its revolutionary Custom Skull Implants in veteran and military hospitals across the country and world.  CCR is the primary supplier database for the U.S. federal government and all vendors have to be registered before the award of a contract or agreement.

According to a story in USA Today, Pentagon officials estimate that up to 360,000 Iraq and Afghanistan veterans have suffered traumatic brain injuries. Many of these brave wounded have damaged or missing portions of their skulls and require cranial implants to be surgically implanted as part of their course of treatment.

Kelyniam Custom Skull Implants (CSI) are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma or birth defects. Streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver patient specific implants to surgeons in as little as 24 hours from the receipt of an order. The ability to provide custom implants quickly and accurately can reduce the time between trauma and implantation and provides surgeons additional treatment options.

“We are very excited to have been approved to market our Custom Skull Implants to our Veteran’s and military hospitals.” said James Ketner, president and founder of Kelyniam.  “Our fighting men and women deserve the finest medical care available and we are confident our implants will greatly improve the quality of life of these wounded warriors.”

Kelyniam Custom Skull Implants have been successfully implanted in patients around the country including its first military patient earlier this month. Feedback from surgeons performing these surgeries has been extremely positive and they have all been ecstatic regarding the quality and fit of the implants and the incredibly fast turnaround time.

Mr. Ketner added, “We recently officially launched our products on October 3^rd at the CNS (Congress of Neurological Surgeons) show in Washington D.C. and had very favorable responses from surgeons and distributors, especially regarding our lead times.  We are on track for a great year in 2012, and believe we will make or exceed our earnings estimates for year-end 2012.”

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

By OMAR FORD

Medical Device Daily Staff Writer

For years, James Ketner manufactured parts for aircraft. That was until about a couple of years ago when Ketner’s company, Kelyniam (New Britain, Connecticut), began supplying Stereolithography models to a device manufacturer. The experience served as a catalyst for Ketner and the company to shift focus to the med-tech industry.

“I saw what [other med-tech companies] were doing and I said, why would you make a mold if you’re only making one piece – a one off item,” Ketner, Kelyniam president/CEO told Medical Device Daily. “You only make a mold if you’re doing 900,000 door handles for Honda, that’s when you make a mold. I thought if we could find a bioimplantable material and machine it, I could do this thing in 24 hours, not four to five weeks.”

As a result, Ketner told MDD that Kelyniam has received FDA approval to begin commercial shipment of its Custom Skull Implants – products that are seen by many in the medical community as game-changers in the world of prosthetics.

“We’ve converted the entire company over to manufacturing this medical device,” he said.

Kelyniam Custom Skull Implants are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma or birth defects. Streamlined CAD/CAM design and manufacturing techniques allow Kelyniam to deliver patient specific implants to surgeons in as little as 24 hours from the receipt of an order.

“I think the thing that’s catching everyone off guard is how fast we can turn this around,” he said. “If you give me the CAD data by 9 a.m. I can have the product on your desk by 9 a.m. the next day.”

The relative quickness in developing the product adds to a better fit for patients, the company said.

“If you take CT scans and it takes you six weeks to get the thing implanted, it’s not going to fit as good, and you can understand why,” he said. The bone is going to move around, it’s going to start healing itself etc. But if you give me a CT scan that’s 24 hours old I can give you a piece that’s going to fit a whole lot better.”

Kelyniam began the development of these new medical devices in 2Q09. In less than two years, the company has perfected a process to quickly and accurately deliver high tolerance, patient specific custom skull implants using PEEKOPTIMA. The regulatory expertise gained during the submission process will be applied to future Kelyniam products.

According to its website, Kelyniam is capable of producing around 40 units per month and that if the firm can produce 40

units a month with its current pricing and share structure that would result in retained earnings of nearly $.18/share. The firm said it anticipated production of more than 40 units per month by the end of 2012. There are also other products in the pipeline.

Kelyniam was originally founded in 2005 and went public in 2008. Since it switched focus, the firm has made several key investments in more firmly settling into the med-device sector.

In June, the company acquired Cranston Holdings a rapid prototyping business with knowledge and expertise in Stereolithography for the medical industry.

“This acquisition will immediately add additional shareholder value by integrating Cranston’s employees and equipment into our infrastructure”, Ketner said in a release detailing the acquisition of the company “Most importantly, Cranston owns an in house developed proprietary software package that will assist us in our ISO 13485, 21 CFR 820 compliance, and that software package is now IP of Kelyniam.”

And last March, the company signed a supply agreement with Invibio (West Conshohocken, Pennsylvania), the exclusive manufacturer of implantable PEEK-OPTIMA polymer. All of Kelyniam’s Maxillofacial and Custom Cranial Implants will be made with Invibio PEEK-OPTIMA polymer.

Plans call for the company to delve deeper into the med-tech territory. It’s a path that Ketner said he didn’t mind staying on and said that the company probably would never go back to its past roots.

“I’m not going to do anything with airplanes anymore,” he said. “I’ve been there and done that. Sitting there trigging out load pads and fastener locations with your TI55 (calculator) can only last for so long. With [medical devices] it’s fun to work everyday. I’m interested and it’s fun to come into the office.”

Omar Ford, 404-262-5546

omar.ford@ahcmedia.com

Canton, Conn.–(BUSINESS WIRE)– Kelyniam Global, Inc. (Pinksheets:KLYG.pk – News), an emerging medical device manufacturing company that recently was granted FDA 510(k) approval, announced today that it has begun commercial shipment of its Custom Skull Implants (CSI). Kelyniam CSI’s are seen by many in the medical community as a game-changer in the world of medical prosthetics.

Kelyniam Custom Skull Implants (CSI) are designed and manufactured for each individual patient to correct or replace bony voids in the cranial skeleton caused by trauma or birth defects. Streamlined CAD/CAM design and manufacturing techniques enable Kelyniam to deliver patient specific implants to surgeons in as little as 24 hours from the receipt of an order. The ability to provide custom implants quickly and accurately can reduce the time between trauma and implantation and provides surgeons additional treatment options.

“We are very excited to have begun commercial shipment of our state-of-the-art Custom Skull Implants,” said James Ketner, president and CEO of Kelyniam. “We are confident our innovative technology, superior form, fit, and function will greatly enhance patient outcomes and empower surgeons by providing them with more and better treatment options than our competitors.”

Kelyniam uses Invibio’s PEEK-OPTIMA® for all of its custom implants. More about Kelyniam’s innovative use of PEEK-OPTIMA can be found at the following link: http://www.plasticstoday.com/articles/peek-empowers-custom-designed-skull-implants0706201101

“We initially became involved with the medical device industry back in 2008 when we were supplying Stereolithography (SLA) models to a device manufacturer,” said Ketner. “When we saw how those implants were being made, we decided that a better manufacturing process could be used to deliver a higher tolerance product and faster deliverable turnaround time. We were producing around 40 units per month when we were making the models, and if we can produce 40 units a month with our current pricing and share structure, that would result in retained earnings of approximately $.18/share. We anticipate production of more than 40 units per month by the end of 2012. We also have other products in development we believe will add additional revenues and earnings.”

The company also intends on becoming fully reporting with the Securities and Exchange Commission once earnings dictate a share price that will allow the company to move to a higher exchange such as the AMEX or NASDAQ.

About Kelyniam Global, Incorporated

Kelyniam Global (Pinksheets:KLYG.pk – News), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

A Canton firm preparing to market custom-made skull implants has purchased a New Britain company whose technology will enhance the acquirer’s business model, officials say.

Kelyniam Global Inc., which is ramping up to begin supplying neurosurgeons and their patients with implants shaped from plastic, acquired the assets of Cranston Holdings LLC. The biotech recently moved from New Britain into 5,000 square feet at 97 River Road in Canton’s Collinsville section.

Kelyniam founder and CEO James Ketner declined to reveal the value of the equity swap involved in the deal.

Cranston’s appeal was its brand of “rapid prototyping” software that will speed Kelyniam’s product development and manufacturing, Ketner said. Rapid prototyping involves designing virtual components using computer-aided design tools and software.

Then, those computer images can be transmitted to a stereolithography machine capable of custom machining a three-dimensional part — in this case a replacement piece of human skull fashioned from medical-grade plastics.

“I can have it in your hand in an hour,” Ketner said of the speed of his computer-aided design to manufacturing setup.

The skull parts are akin to ones used to repair the head wound Congresswoman Gabrielle Giffords sustained in a gun attack last January in Tucson, Ariz.

Kelyniam recently won Food & Drug Administrtation approval to market, starting as early as July, its custom skull implants. However, Ketner said, the company’s ability to comply with ISO 13485 standards for on-site manufacturing of sterile components is enhanced by its acquisition of Cranston and its rapid prototyping software.

Former Cranston President Chris Breault is joining Kelyniam to run its manufacturing operations. Breault also takes a seat on the board.

Kelyniam trades publicly over the counter. Its 2010 revenues of about $400,000 was from its aerospace-automotive design consulting work, Ketner said.

Cranston’s sales last year were about $600,000.

With the addition of Cranston’s six workers, Kelyniam now has a staff of 11.

Staffing is likely to increase, Ketner said, if the inflow of orders — some 50 so far — from neurosurgeons from as far off as Florida, Texas and California continues unabated. He declined to elaborate on sales and staffing targets.

About Kelyniam Global, Incorporated:

Kelyniam Global, Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today’s technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipate,” “believes,” “estimate,” “expect,” “should,” “intend,” “projects,” “objective” and “appears” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.